Table 1.
Characteristics of waitlisted and not waitlisted incident ESRD patientsa
| Characteristic | Network 6 Incident ESRD Patients, n = 35,346 | Waitlisted, n = 4153 (11.8%)
|
Not Waitlisted, n = 31,193 (88.2%)
|
Crude OR for Waitlisting (95% CI) | P Valuee | |
|---|---|---|---|---|---|---|
| P Value for Waitlisting Difference | ||||||
| Distance to transplant facility (mi) | P <0.0006 | |||||
| <20 | 8585 (24.9%) | 1102 (27.0%) | 7483 (24.6%) | Reference | ||
| 20 to 39 | 6939 (20.1%) | 830 (20.4%) | 6109 (20.0%) | 0.92 (0.84 to 1.02) | 0.1006 | |
| 40 to 69 | 7089 (20.5%) | 814 (20.0%) | 6275 (20.6%) | 0.88 (0.80 to 0.97) | 0.0100 | |
| 70 to 99 | 6008 (17.4%) | 634 (15.5%) | 5374 (17.6%) | 0.80 (0.72 to 0.89) | <0.0001 | |
| 100 to 149 | 4124 (11.9%) | 532 (13.0%) | 3592 (11.8%) | 1.01 (0.90 to 1.12) | 0.9199 | |
| ≥150 | 1801 (5.2%) | 166 (4.1%) | 1635 (5.4%) | 0.69 (0.58 to 0.82) | <0.0001 | |
| Race | P = 0.0004 | |||||
| white | 15,117 (42.8%) | 1670 (40.2%) | 13,447 (43.1%) | Reference | 0.0004 | |
| black | 20,229 (57.2%) | 2483 (59.8%) | 17,746 (56.9%) | 1.13 (1.06 to 1.20) | ||
| Age (yr) | P <0.0001 | |||||
| 20 to 39 | 3624 (10.2%) | 1240 (19.9%) | 2384 (7.6%) | Reference | ||
| 40 to 49 | 4712 (13.3%) | 1070 (25.7%) | 3642 (11.7%) | 0.57 (0.51 to 0.62) | <0.0001 | |
| 50 to 59 | 7151 (20.2%) | 1174 (28.3%) | 5977 (19.2%) | 0.38 (0.34 to 0.41) | <0.0001 | |
| 60 to 69 | 8587 (24.3%) | 602 (14.5%) | 7985 (25.6%) | 0.15 (0.13 to 0.16) | <0.0001 | |
| ≥70 | 11,272 (32.0%) | 67 (1.6%) | 11,205 (35.9%) | 0.01 (0.01 to 0.02) | <0.0001 | |
| Gender | P <0.0001 | |||||
| male | 17,675 (50.1%) | 2429 (58.5%) | 15,246 (48.9%) | Reference | ||
| female | 17,671 (49.9%) | 1724 (41.5%) | 15,947 (51.1%) | 0.70 (0.64 to 0.73) | <0.0001 | |
| Primary Cause ESRD | P <0.0001 | |||||
| diabetes | 15,721 (44.5%) | 1521 (36.6%) | 14,200 (45.5%) | Reference | ||
| GN | 2833 (8.0%) | 756 (18.2%) | 2077 (6.7%) | 3.40 (3.08 to 3.75) | 0.0001 | |
| hypertension | 10,636 (30.1%) | 1063 (25.6%) | 9573 (30.7%) | 1.04 (0.96 to 1.13) | 0.3923 | |
| otherc | 6156 (17.4%) | 813 (19.6%) | 5343 (17.1%) | 1.42 (1.30 to 1.56) | 0.0001 | |
| Total comorbiditiesd | P <0.0001 | |||||
| 0 | 1478 (4.2%) | 297 (7.1%) | 1181 (3.8%) | Reference | ||
| 1 | 8021 (22.7%) | 1701 (41.0%) | 6320 (20.3%) | 1.07 (0.93 to 1.23) | 0.3351 | |
| 2 | 8387 (23.7%) | 969 (23.3%) | 7418 (23.8%) | 0.52 (0.45 to 0.60) | <0.0001 | |
| 3 | 7222 (20.4%) | 727 (17.5%) | 6495 (20.8%) | 0.45 (0.38 to 0.52) | <0.0001 | |
| 4 | 4743 (13.4%) | 307 (7.4%) | 4436 (14.2%) | 0.28 (0.23 to 0.33) | <0.0001 | |
| ≥5 | 5495 (15.6%) | 152 (3.7%) | 5343 (17.1%) | 0.11 (0.09 to 0.14) | <0.0001 | |
| Body mass index (kg/m2)b | P <0.0001 | |||||
| underweight (<18.5) | 2112 (6.2%) | 116 (2.9%) | 1996 (6.6%) | 0.51 (0.42 to 0.62) | <0.0001 | |
| normal (18.5 to 24.9) | 12,885 (37.7%) | 1320 (32.5%) | 11,565 (38.5%) | Reference | ||
| overweight (25 to 29.9) | 9555 (28.0%) | 1315 (32.4%) | 8240 (17.4%) | 1.40 (1.29 to 1.52) | <0.0001 | |
| obese (30.0 to 39.9) | 8089 (23.7%) | 1163 (28.7%) | 6926 (23%) | 1.47 (1.35 to 1.60) | <0.0001 | |
| morbidly obese (>40) | 1497 (4.4%) | 144 (3.5%) | 1353 (4.5%) | 0.93 (0.78 to 1.12) | 0.4490 | |
| Erythropoietin use (%) | P <0.0001 | |||||
| 9246 (26.2%) | 1262 (30.4%) | 7984 (25.6%) | 1.27 (1.18 to 1.36) | <0.0001 | ||
| Mean hemoglobin (±SD) (g/dl) | P = 0.1233 | |||||
| 9.4 ± 4.4 | 9.3 ± 3.9 | 9.4 ± 4.4 | 0.99 (0.98 to 1.01) | 0.1230 | ||
| Mean albumin (±SD) (g/dl) | P <0.0001 | |||||
| 2.56 ± 1.55 | 2.71 ± 01.51 | 2.54 ± 1.56 | 1.07 (1.05 to 1.09) | <0.0001 | ||
| Degree of rurality | P <0.0001 | |||||
| urban | 22,270 (63.0%) | 2761 (66.5%) | 19,509 (62.5%) | Reference | ||
| large rural | 6958 (19.7%) | 759 (18.3%) | 6199 (19.9%) | 0.87 (0.79 to 0.94) | 0.0009 | |
| small rural | 3910 (11.1%) | 391 (9.4%) | 3,519 (11.3%) | 0.79 (0.70 to 0.88) | <0.0001 | |
| small remote rural | 2208 (6.2%) | 242 (5.8%) | 1966 (6.3%) | 0.87 (0.76 to 1.00) | 0.0497 | |
| Neighborhood povertyb (% of census below poverty line) | P <0.0001 | |||||
| 0 to 4.9% (wealthiest) | 2850 (8.3%) | 477 (11.7%) | 2373 (7.8%) | 1.41 (1.25 to 1.60) | <0.0001 | |
| 5 to 9.9% | 7255 (21.1%) | 967 (23.8%) | 6258 (20.7%) | 1.09 (0.98 to 1.20) | 0.1083 | |
| 10 to 14.9% | 6594 (19.2%) | 822 (20.2%) | 5772 (19.1%) | Reference | ||
| 15 to 19.9% | 6045 (17.6%) | 716 (17.6%) | 5329 (17.6%) | 0.94 (0.85 to 1.05) | 0.2858 | |
| 20 to 24.9% | 4718 (13.8%) | 433 (10.7%) | 4285 (14.2%) | 0.71 (0.63 to 0.80) | <0.0001 | |
| ≥25% (poorest) | 6873 (20.0%) | 648 (16.0%) | 6225 (20.6%) | 0.73 (0.66 to 0.82) | <0.0001 | |
Clinical measurements were measured at dialysis initiation.
Columns do not add up to total population because of missing values (800 patients missing distance, 1208 patients missing body mass index measurements, 1041 missing neighborhood poverty, 3 missing erythropoietin status).
Other primary causes of ESRD (<5% of total) included secondary GN/vasculitis, interstitial nephritis/pyelonephritis, cystic/hereditary/congenital disease, neoplasms/tumors, and miscellaneous conditions.
Comorbid conditions included congestive heart failure, ischemic heart disease, myocardial infarction, cardiac arrest, cardiac dysrhythmia, pericarditis, cerebrovascular disease, peripheral vascular disease, history of hypertension, diabetes (primary or contributing), chronic obstructive pulmonary disease, tobacco use, malignant neoplasm (cancer), alcohol dependence, drug dependence, HIV positive status, AIDS, inability to ambulate, and inability to transfer.
P value associated with crude OR for waitlisting.